News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

November

11

electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

12

electroCore Announces Full Year 2024 Financial Results

Record full-year 2024 net sales of $25.2 million increased 57% over $16.0 million for the full year 2023 driven by...

6

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

13

electroCore Announces Third Quarter 2024 Financial Results

Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase...

21

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents

Four patents issued expanding claims related to delivery of nVNS and other therapies using...

Recent developments

November

11

electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

March

12

electroCore Announces Full Year 2024 Financial Results

March

6

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

November

13

electroCore Announces Third Quarter 2024 Financial Results

September

21

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents